Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Abstract

Prognostic markers, such as NPM1, Flt3-ITD, and cytogenetic abnormalities have made it possible to formulate aggressive treatment plans for unfavorable acute myeloid leukemia (AML). However, the long-term survival of AML with unfavorable factors remains unsatisfactory. The latest data indicate that the standard dose of daunorubicin (DNR) at 45 mg/m2 is inferior to high dose 90 mg/m2 for induction therapy. The rates of complete remission and overall survival are significantly better in the high dose induction regimen. New regimens exploring the new liposomal encapsulation of Ara-C and DNR as well as addition of gemtuzumab ozogamicin monoclonal antibody have been studied. New agents, including the nucleoside analogues (clofarabine, sapacitabine, elacytarabine), FLT3 inhibitor (sorafenib), farnesyl-transferase inhibitor (tipifarnib), histone deacetylase inhibitor (vorinostat), lenalidomide, as well as DNA methyltransferase inhibitors (decitabine, azacitidine), were recently reported for AML treatment in the 2009 ASH annual meeting. This review also summarizes the updates of the clinical trials on novel agents including voreloxin, AS1413, behenoylara-C, ARRY520, ribavirin, AZD1152, AZD6244, and terameprocol (EM-1421) from the 2009 ASH annual meeting.

DOI: 10.1186/1756-8722-3-17

Extracted Key Phrases

6 Figures and Tables

05010020102011201220132014201520162017
Citations per Year

223 Citations

Semantic Scholar estimates that this publication has 223 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Zhu2010NovelAA, title={Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights}, author={Xiong-peng Zhu and Yuehua Ma and Delong Liu}, booktitle={Journal of hematology & oncology}, year={2010} }